Latest News & Momentum.
» Connect with us on LinkedIn
CAMPER: mechanistic artificial intelligence for designing peptides that target MRSA persisters
Scientific Publication: Nature Communications publication from BLASTID SAB members and collaborators providing description of fabrication and surface treatment of microfluidic devices for microscopic visualization of antimicrobial activity on S. aureus. (March 9, 2026)
ADLM 2025 Poster Presentation
Poster Presentation: Demonstration of ultra-rapid isolation of pathogens from blood samples and compatibility with FDA-approved automated AST system (July 29, 2025)
BLASTID and Q-linea announce collaboration and conference presentation
Press Release: BLASTID and Q-linea announced a successful proof-of-concept collaboration delivering ultra-rapid, direct-from-whole-blood pathogen isolation, enrichment, and phenotypic antibiotic susceptibility testing (AST) with results presented at the ADLM 2025 Conference in Chicago (July 29, 2025)
ARPA-H announces award to address the rapidly growing threat of antimicrobial resistance and drive antibiotic discovery to improve health outcomes
In the News: ARPA-H awarded up to $104 million through its Defeating Antibiotic Resistance through Transformative Solutions (DARTS) project, led by BLASTID co-founder and Harvard Medical School professor Dr. Johan Paulsson, to develop ultra-high-speed diagnostic and screening platforms that rapidly identify resistant bacteria, match patients to the right antibiotic, and accelerate discovery of new antibiotics (Sept. 27, 2023)
HMS Researcher to Lead $104 Million Federal Project Tackling Antibiotic Resistance
In the News: BLASTID co-founder and HMS systems biology professor Dr. Johan Paulsson will lead a multi-institutional $104 million ARPA-H award uniting 25 research groups across academia, hospitals, and industry (including Harvard spinout BLASTID) to develop microscopy, microfluidics, single-cell assay, and machine-learning technologies that rapidly diagnose bacterial infections, accelerate antibiotic discovery, and combat the growing crisis of antimicrobial resistance (Sept. 27, 2023)